Northern Trust Corp decreased its position in CTI BioPharma Corp (NASDAQ:CTIC) by 5.2% during the 2nd quarter, Holdings Channel reports. The firm owned 538,290 shares of the biopharmaceutical company’s stock after selling 29,433 shares during the quarter. Northern Trust Corp’s holdings in CTI BioPharma were worth $463,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of CTIC. SG Americas Securities LLC grew its holdings in CTI BioPharma by 44.0% in the second quarter. SG Americas Securities LLC now owns 56,132 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 17,163 shares during the last quarter. Fosun International Ltd grew its holdings in CTI BioPharma by 52.9% in the second quarter. Fosun International Ltd now owns 459,274 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 158,846 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in CTI BioPharma by 24.5% in the second quarter. Renaissance Technologies LLC now owns 1,596,587 shares of the biopharmaceutical company’s stock valued at $1,372,000 after purchasing an additional 314,235 shares during the last quarter. 47.04% of the stock is currently owned by institutional investors.
CTI BioPharma stock opened at $0.82 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.15 and a quick ratio of 3.15. CTI BioPharma Corp has a fifty-two week low of $0.60 and a fifty-two week high of $2.04. The stock’s fifty day moving average is $0.80 and its two-hundred day moving average is $0.84.
CTI BioPharma (NASDAQ:CTIC) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.19). The company had revenue of $0.42 million for the quarter. CTI BioPharma had a negative return on equity of 77.77% and a negative net margin of 225.01%.
About CTI BioPharma
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.
Recommended Story: Stop Order
Want to see what other hedge funds are holding CTIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CTI BioPharma Corp (NASDAQ:CTIC).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.